Fungal Infection in Co-infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review
Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infectio...
Saved in:
| Published in: | Frontiers in microbiology Vol. 13; p. 888452 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
06.07.2022
|
| Subjects: | |
| ISSN: | 1664-302X, 1664-302X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were
Aspergillus
spp.,
Mucor
spp.,
Rhizopus
spp., and
Candida
spp. reported in study patients. The mortality rate was 54.6%, and the rate of discharged patients was 45.3%. Remdesivir and voriconazole were the most commonly used antiviral and antifungal agents for the treatment of patients. The global prevalence of COVID-19-related deaths is 6.6%. Our results showed that 54.6% of COVID-19 patients with fungal co-infections died. Thus, this study indicated that fungal co-infection and COVID-19 could increase mortality. Targeted policies should be considered to address this raised risk in the current pandemic. In addition, fungal infections are sometimes diagnosed late in patients with COVID-19, and the severity of the disease worsens, especially in patients with underlying conditions. Therefore, patients with fungal infections should be screened regularly during the COVID-19 pandemic to prevent the spread of the COVID-19 patients with fungal co-infection. |
|---|---|
| AbstractList | Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were Aspergillus spp., Mucor spp., Rhizopus spp., and Candida spp. reported in study patients. The mortality rate was 54.6%, and the rate of discharged patients was 45.3%. Remdesivir and voriconazole were the most commonly used antiviral and antifungal agents for the treatment of patients. The global prevalence of COVID-19-related deaths is 6.6%. Our results showed that 54.6% of COVID-19 patients with fungal co-infections died. Thus, this study indicated that fungal co-infection and COVID-19 could increase mortality. Targeted policies should be considered to address this raised risk in the current pandemic. In addition, fungal infections are sometimes diagnosed late in patients with COVID-19, and the severity of the disease worsens, especially in patients with underlying conditions. Therefore, patients with fungal infections should be screened regularly during the COVID-19 pandemic to prevent the spread of the COVID-19 patients with fungal co-infection.Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were Aspergillus spp., Mucor spp., Rhizopus spp., and Candida spp. reported in study patients. The mortality rate was 54.6%, and the rate of discharged patients was 45.3%. Remdesivir and voriconazole were the most commonly used antiviral and antifungal agents for the treatment of patients. The global prevalence of COVID-19-related deaths is 6.6%. Our results showed that 54.6% of COVID-19 patients with fungal co-infections died. Thus, this study indicated that fungal co-infection and COVID-19 could increase mortality. Targeted policies should be considered to address this raised risk in the current pandemic. In addition, fungal infections are sometimes diagnosed late in patients with COVID-19, and the severity of the disease worsens, especially in patients with underlying conditions. Therefore, patients with fungal infections should be screened regularly during the COVID-19 pandemic to prevent the spread of the COVID-19 patients with fungal co-infection. Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were Aspergillus spp., Mucor spp., Rhizopus spp., and Candida spp. reported in study patients. The mortality rate was 54.6%, and the rate of discharged patients was 45.3%. Remdesivir and voriconazole were the most commonly used antiviral and antifungal agents for the treatment of patients. The global prevalence of COVID-19-related deaths is 6.6%. Our results showed that 54.6% of COVID-19 patients with fungal co-infections died. Thus, this study indicated that fungal co-infection and COVID-19 could increase mortality. Targeted policies should be considered to address this raised risk in the current pandemic. In addition, fungal infections are sometimes diagnosed late in patients with COVID-19, and the severity of the disease worsens, especially in patients with underlying conditions. Therefore, patients with fungal infections should be screened regularly during the COVID-19 pandemic to prevent the spread of the COVID-19 patients with fungal co-infection. Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were Aspergillus spp., Mucor spp., Rhizopus spp., and Candida spp. reported in study patients. The mortality rate was 54.6%, and the rate of discharged patients was 45.3%. Remdesivir and voriconazole were the most commonly used antiviral and antifungal agents for the treatment of patients. The global prevalence of COVID-19-related deaths is 6.6%. Our results showed that 54.6% of COVID-19 patients with fungal co-infections died. Thus, this study indicated that fungal co-infection and COVID-19 could increase mortality. Targeted policies should be considered to address this raised risk in the current pandemic. In addition, fungal infections are sometimes diagnosed late in patients with COVID-19, and the severity of the disease worsens, especially in patients with underlying conditions. Therefore, patients with fungal infections should be screened regularly during the COVID-19 pandemic to prevent the spread of the COVID-19 patients with fungal co-infection. |
| Author | Seyedjavadi, Sima Sadat Goudarzi, Mehdi Nasiri, Mohammad Javad Razzaghi-Abyaneh, Mehdi Bagheri, Parmida |
| AuthorAffiliation | 2 Department of Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University , Tehran , Iran 1 Department of Mycology, Pasteur Institute of Iran , Tehran , Iran 3 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences , Tehran , Iran |
| AuthorAffiliation_xml | – name: 2 Department of Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University , Tehran , Iran – name: 1 Department of Mycology, Pasteur Institute of Iran , Tehran , Iran – name: 3 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences , Tehran , Iran |
| Author_xml | – sequence: 1 givenname: Sima Sadat surname: Seyedjavadi fullname: Seyedjavadi, Sima Sadat – sequence: 2 givenname: Parmida surname: Bagheri fullname: Bagheri, Parmida – sequence: 3 givenname: Mohammad Javad surname: Nasiri fullname: Nasiri, Mohammad Javad – sequence: 4 givenname: Mehdi surname: Razzaghi-Abyaneh fullname: Razzaghi-Abyaneh, Mehdi – sequence: 5 givenname: Mehdi surname: Goudarzi fullname: Goudarzi, Mehdi |
| BookMark | eNp1kk1v3CAQhlGVqkm3-QG9cezFG_NhDD1UitymXSnSVk2_bojF4w2RDRuwt8q_L95NpaZSEQIG5n00Gt6X6MQHDwi9JuWSMakuusHZzZKWlC6llLyiz9AZEYIXrKQ_T_46n6LzlO7KPHhJ8_oCnbJK1lUl6Bmaria_NT1e-Q7s6ILHzuMmFO4QQ4s_m9GBHxP-4cZb3Ky_r94XRL3Flx6v9xD3Dn7h0OHGJMBfYBfimC4OwQ1EBwkb3-KbhzTCkEE2p8yKV-h5Z_oE54_7An27-vC1-VRcrz-umsvrwnJOx3lVRtbMyKpWsgK-qTpuW6CgBLN1DZapqmZMEZMn61phDANgxnStNJayBVoduW0wd3oX3WDigw7G6cNFiFttYi6rB602AIR20AquuGCtrHKDyhK6siXM5iIW6N2RtZs2A7Q2NyWa_gn06Yt3t3ob9lpRJYWoMuDNIyCG-wnSqAeXLPS98RCmpKlQnJOaCJZT62OqjSGlCJ22bjTz92Sy6zUp9ewBffCAnj2gjx7ISvKP8k-B_9f8BuW5tsU |
| CitedBy_id | crossref_primary_10_3390_microorganisms11092326 crossref_primary_10_1002_dc_70014 crossref_primary_10_3390_medicina59071253 crossref_primary_10_3389_fcimb_2023_1220012 crossref_primary_10_1016_j_cegh_2024_101603 crossref_primary_10_1038_s41467_024_52913_2 crossref_primary_10_1021_acsomega_5c01914 crossref_primary_10_1007_s00284_024_03916_1 crossref_primary_10_1186_s12866_025_03989_3 crossref_primary_10_1097_TP_0000000000005033 crossref_primary_10_7759_cureus_61629 crossref_primary_10_3390_vaccines11030555 crossref_primary_10_1007_s00408_023_00638_2 crossref_primary_10_1055_s_0043_1767716 crossref_primary_10_7705_biomedica_7251 crossref_primary_10_3389_fmed_2025_1652051 crossref_primary_10_1080_23744235_2024_2425712 crossref_primary_10_3390_microorganisms12071468 crossref_primary_10_1186_s13104_024_07010_4 crossref_primary_10_13005_ojc_400302 crossref_primary_10_22207_JPAM_18_3_47 crossref_primary_10_3390_pathogens12101206 crossref_primary_10_3390_jof9060633 crossref_primary_10_3389_fpubh_2023_1195048 crossref_primary_10_7759_cureus_50321 crossref_primary_10_3390_jof11090617 crossref_primary_10_5114_bta_2023_130727 crossref_primary_10_1016_j_hermed_2023_100810 crossref_primary_10_1007_s00408_023_00642_6 crossref_primary_10_3390_jof9020130 crossref_primary_10_1002_ccr3_7882 crossref_primary_10_1097_IO9_0000000000000198 crossref_primary_10_1186_s12879_024_10373_5 |
| Cites_doi | 10.3390/jof7030220 10.3390/vaccines8030544 10.3390/jof6030163 10.1016/j.ajem.2020.09.032 10.18502/fem.v6i1.7684 10.1016/j.mycmed.2017.12.008 10.1007/s11046-020-00462-9 10.1155/2021/9745701 10.1016/j.idcr.2021.e01153 10.1093/ofid/ofaa633 10.46234/ccdcw2020.032 10.18203/issn.2454-5929.ijohns20211583 10.1111/myc.13185 10.1007/s12098-020-03263-6 10.2147/IDR.S314029 10.1177/11206721211009450 10.1002/jmv.26237 10.1016/j.jcrc.2020.07.002 10.1016/j.cmi.2020.07.041 10.1016/j.mycmed.2021.101175 10.1101/2021.08.09.21261555 10.5946/ce.2020.180 10.1016/j.mmcr.2020.06.006 10.1007/s11046-021-00584-8 10.1099/acmi.0.000201 10.3390/jof7030174 10.18502/cmm.7.2.7031 10.1016/S0140-6736(20)30211-7 10.1007/s15010-020-01458-9 10.18297/jri/vol5/iss1/31 10.1016/j.ijid.2020.06.012 10.1016/j.idcr.2020.e00935 10.1016/j.ijsu.2010.02.007 10.1016/j.mycmed.2020.101039 10.1080/23744235.2021.1890331 10.1073/pnas.2119893119 10.1016/j.mmcr.2020.07.001 10.3390/jof7100877 10.1177/2324709620930540 10.1016/j.tmaid.2020.101752 10.7759/cureus.10726 10.3390/jof6020079 10.1016/j.micinf.2021.104806 10.1186/s41983-021-00355-8 10.1016/j.mmcr.2021.03.006 10.1007/s10461-020-02983- 10.1016/S2213-2600(20)30079-5 10.1136/bcr-2021-241663 10.3390/jof6030098 10.18231/j.ijmr.2021.051 10.7861/clinmed.2020-0239 10.1016/j.ijid.2021.02.071 10.1016/j.mmcr.2020.11.003 10.7759/cureus.13163 10.1111/tid.13652 10.1016/j.pdpdt.2021.102281 10.1016/j.mmcr.2020.11.004 10.18502/ijm.v11i6.2216 10.1016/j.jiac.2021.02.026 10.1097/MD.0000000000025173 10.1016/j.idcr.2021.e01244 10.1007/s15010-020-01561-x 10.1016/j.mmcr.2020.06.005 10.1016/j.mycmed.2021.101125 10.1089/aid.2020.0284 10.1007/s42399-020-00574-9 10.18632/aging.202742 10.1093/cid/ciaa1342 10.1016/j.mmcr.2020.06.002 10.1016/j.ijmmb.2021.05.009 10.2174/156802662022200917110102 10.1016/j.radcr.2020.09.026 10.1186/s13054-020-03046-7 10.1007/s11046-020-00505-1 10.22551/2020.28.0703.10172 10.1016/j.idnow.2021.01.004 10.1111/myc.13135 10.1111/myc.13155 10.3389/fpubh.2020.00152 10.38179/ijcr.v2i1.102 10.1016/j.cmi.2020.06.025 10.1097/IOP.0000000000001889 10.1016/j.neurad.2021.05.007 10.1177/2050313X211048279 10.1016/j.riam.2020.07.001 10.1101/2020.02.07.937862 10.3390/jof6040279 10.1007/s11046-020-00493-2 10.1093/cid/ciaa530 10.1007/s12070-021-02574-0 10.1016/j.ijscr.2021.105957 10.1016/j.mmcr.2020.05.001 10.1111/bjd.19163 10.3389/fcvm.2021.695206 10.1016/j.acra.2020.04.016 10.1016/j.genrep.2020.100910 10.18203/issn.2454-5929.ijohns20213287 10.1016/S1473-3099(20)30200-0 10.1016/j.rmcr.2021.101367 10.14740/jmc3637 10.1080/01676830.2021.1903044 10.1177/2324709620972244 10.7759/cureus.16152 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi. Copyright © 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi. 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi |
| Copyright_xml | – notice: Copyright © 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi. – notice: Copyright © 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi. 2022 Seyedjavadi, Bagheri, Nasiri, Razzaghi-Abyaneh and Goudarzi |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fmicb.2022.888452 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-302X |
| ExternalDocumentID | oai_doaj_org_article_9bee12fed649463d8555600ef0d13c87 PMC9298665 10_3389_fmicb_2022_888452 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK ECGQY GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c442t-c449a873a857985e4b5f4cde2e963c77ec39573391a91a3fd6aa3ee3aafd8ac23 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 41 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000829411900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-302X |
| IngestDate | Fri Oct 03 12:51:44 EDT 2025 Tue Sep 30 16:51:57 EDT 2025 Fri Sep 05 07:44:42 EDT 2025 Sat Nov 29 02:56:52 EST 2025 Tue Nov 18 21:18:30 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-c449a873a857985e4b5f4cde2e963c77ec39573391a91a3fd6aa3ee3aafd8ac23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Matthaios Papadimitriou-Olivgeris, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland This article was submitted to Virology, a section of the journal Frontiers in Microbiology Reviewed by: Raquel Sabino, National Institute of Health Dr. Ricardo Jorge, Portugal; Tong-Bao Liu, Southwest University, China |
| OpenAccessLink | https://doaj.org/article/9bee12fed649463d8555600ef0d13c87 |
| PMID | 35875562 |
| PQID | 2694417163 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9bee12fed649463d8555600ef0d13c87 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9298665 proquest_miscellaneous_2694417163 crossref_citationtrail_10_3389_fmicb_2022_888452 crossref_primary_10_3389_fmicb_2022_888452 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-06 |
| PublicationDateYYYYMMDD | 2022-07-06 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in microbiology |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Chaudhary (B16) 2022; 6 Waizel-Haiat (B98) 2021; 13 Mishra (B54) 2021; 7 Veisi (B95) 2021 Pemán (B67) 2020; 37 Werthman-Ehrenreich (B100) 2021; 42 Khan (B41) 2020; 7 Antinori (B9) 2020; 38 Posteraro (B70) 2020; 6 Mehrabi (B48) 2021; 2021 Hoenigl (B32) 2020; 73 Chen (B17) 2020; 395 Saldanha (B79) 2021 Sharma (B85) 2021; 31 Garcia-Vidal (B28) 2021; 27 Teixeira (B93) 2021; 34 Khodavaisy (B43) 2021; 7 Sadeghi (B78) 2018; 28 Rubiano (B77) 2021; 8 Mehta (B49) 2020; 12 Sari (B80) 2021; 100 Basso (B12) 2021; 186 Mitaka (B55) 2020; 63 Al Osta (B2) 2021; 2 Jamzivar (B35) 2019; 11 Moher (B57) 2010; 8 Yang (B101) 2021; 93 Benedetti (B13) 2021; 31 Jin (B36) 2020; 8 Gorbalenya (B30) 2020 Nasir (B59) 2020; 63 Nasri (B60) 2020; 185 Khatri (B42) 2021; 31 Merchant (B52) 2021; 24 Ashour (B11) 2021; 48 Seitz (B82) 2020; 48 Kalantari (B38) 2020; 21 Costache (B18) 2021; 7 Imoto (B34) 2021; 27 Galván Casas (B27) 2020; 183 Ali (B6) 2021; 25 Meijer (B50) 2020; 6 Bowalekar (B14) 2021; 8 Abdalla (B1) 2020; 22 Ventoulis (B96) 2020; 6 Revannavar (B74) 2021; 14 Albashir (B3) 2020; 20 Almeida (B7) 2021; 7 Aldaas (B4) 2021; 5 Passarelli (B65) 2020; 2 Schein (B81) 2020; 30 Farhan (B24) 2021; 105 Peng (B68) 2021; 13 Yang (B103) 2020; 8 Lescure (B45) 2020; 20 De Francesco (B20) 2020; 8 Singhal (B89) 2020; 87 Dos Santos (B22) 2020; 97 Wang (B99) 2020; 24 Chang (B15) 2020; 8 Pasero (B64) 2021; 49 Viceconte (B97) 2021; 53 Ohashi (B62) 2021; 9 Trovato (B94) 2021; 32 Fernandez (B25) 2021; 31 Nehara (B61) 2021; 39 Kanwar (B40) 2021; 7 Kalpana (B39) 2021; 42 Falces-Romero (B23) 2020; 63 Dallalzadeh (B19) 2021 Legnani (B44) 2021; 51 Mohamed (B56) 2021; 31 Robinson (B75) 2022; 119 Maini (B46) 2021; 82 Muthu (B58) 2021; 186 Patel (B66) 2021; 37 Song (B90) 2020; 185 Alekseyev (B5) 2021; 12 Alobaid (B8) 2021; 3 Rawson (B73) 2020; 71 Do Monte Junior (B21) 2020; 53 Martins (B47) 2021; 31 Yang (B102) 2021; 23 Prattes (B71) 2021; 31 Singh (B88) 2021; 13 Senok (B83) 2021; 14 Ghelfenstein-Ferreira (B29) 2021; 31 Hughes (B33) 2020; 26 Team (B92) 2020; 2 Mekonnen (B51) 2021; 37 Haglund (B31) 2021; 31 Omidi (B63) 2021; 8 Talento (B91) 2020; 6 Radpour (B72) 2020; 27 Placik (B69) 2020; 15 Singh (B87) 2021 Arana (B10) 2021; 23 Roushdy (B76) 2021; 57 Johnson (B37) 2021; 32 Mirzaei (B53) 2021; 25 Zheng (B104) 2003; 2 Silva (B86) 2020; 20 Shah (B84) 2020; 8 Flikweert (B26) 2020; 59 |
| References_xml | – volume: 7 year: 2021 ident: B7 article-title: Emergence of Candida auris in Brazil in a COVID-19 intensive care unit. publication-title: J. Fungi doi: 10.3390/jof7030220 – volume: 8 year: 2020 ident: B20 article-title: Pneumocystis jirevocii and SARS-CoV-2 co-infection: a common feature in transplant recipients? publication-title: Vaccines doi: 10.3390/vaccines8030544 – volume: 6 year: 2020 ident: B70 article-title: Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report. publication-title: J. Fungi doi: 10.3390/jof6030163 – volume: 42 start-page: e264.e5 year: 2021 ident: B100 article-title: Mucormycosis with orbital compartment syndrome in a patient with COVID-19. publication-title: Am. J. Emerg. Med. doi: 10.1016/j.ajem.2020.09.032 – volume: 6 year: 2022 ident: B16 article-title: Renal mucormycosis following COVID-19 treatment with immune modulators: a case report. publication-title: Front. Emerg. Med. doi: 10.18502/fem.v6i1.7684 – volume: 28 start-page: 51 year: 2018 ident: B78 article-title: Emergence of non-Candida albicans species: epidemiology, phylogeny and fluconazole susceptibility profile. publication-title: J. Mycol. Med. doi: 10.1016/j.mycmed.2017.12.008 – volume: 185 start-page: 599 year: 2020 ident: B90 article-title: Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. publication-title: Mycopathologia doi: 10.1007/s11046-020-00462-9 – volume: 2021 year: 2021 ident: B48 article-title: Sinoorbital mucormycosis associated with corticosteroid therapy in COVID-19 infection. publication-title: Case Rep. Ophthalmol. Med. doi: 10.1155/2021/9745701 – volume: 24 year: 2021 ident: B52 article-title: Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome. publication-title: IDCases doi: 10.1016/j.idcr.2021.e01153 – volume: 8 year: 2021 ident: B77 article-title: Pneumocystis and severe acute respiratory syndrome coronavirus 2 coinfection: a case report and review of an emerging diagnostic dilemma. publication-title: Open Forum Infect. Dis. doi: 10.1093/ofid/ofaa633 – volume: 2 start-page: 113 year: 2020 ident: B92 article-title: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. publication-title: China CDC Wkly. doi: 10.46234/ccdcw2020.032 – volume: 7 start-page: 867 year: 2021 ident: B54 article-title: A case series of invasive mucormycosis in patients with COVID-19 infection. publication-title: Int. J. Otorhinolaryngol. Head Neck Surg. doi: 10.18203/issn.2454-5929.ijohns20211583 – volume: 63 start-page: 1368 year: 2020 ident: B55 article-title: Putative invasive pulmonary aspergillosis in critically ill patients with COVID−19: an observational study from New York City. publication-title: Mycoses doi: 10.1111/myc.13185 – volume: 87 start-page: 281 year: 2020 ident: B89 article-title: A review of coronavirus disease-2019 (COVID-19). publication-title: Indian J. Pediatr. doi: 10.1007/s12098-020-03263-6 – volume: 14 start-page: 2289 year: 2021 ident: B83 article-title: Coinfections in patients hospitalized with COVID-19: a descriptive study from the United Arab Emirates. publication-title: Infect. Drug Resist. doi: 10.2147/IDR.S314029 – year: 2021 ident: B95 article-title: Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. publication-title: Eur. J. Ophthalmol. doi: 10.1177/11206721211009450 – volume: 93 start-page: 257 year: 2021 ident: B101 article-title: Obesity aggravates COVID−19: a systematic review and meta−analysis. publication-title: J. Med. Virol. doi: 10.1002/jmv.26237 – volume: 59 start-page: 149 year: 2020 ident: B26 article-title: Late histopathologic characteristics of critically ill COVID-19 patients: different phenotypes without evidence of invasive aspergillosis, a case series. publication-title: J. Crit. Care doi: 10.1016/j.jcrc.2020.07.002 – volume: 27 start-page: 83 year: 2021 ident: B28 article-title: Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2020.07.041 – volume: 31 year: 2021 ident: B47 article-title: COVID-19 and invasive fungal coinfections: a case series at a Brazilian referral hospital. publication-title: J. Mycol. Med. doi: 10.1016/j.mycmed.2021.101175 – year: 2021 ident: B87 article-title: Mixed invasive molds among COVID-19 patients. publication-title: medRxiv Preprint doi: 10.1101/2021.08.09.21261555 – volume: 53 start-page: 746 year: 2020 ident: B21 article-title: Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. publication-title: Clin. Endosc. doi: 10.5946/ce.2020.180 – volume: 31 start-page: 15 year: 2021 ident: B29 article-title: Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU–A case report. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.06.006 – volume: 186 start-page: 739 year: 2021 ident: B58 article-title: Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. publication-title: Mycopathologia doi: 10.1007/s11046-021-00584-8 – volume: 3 year: 2021 ident: B8 article-title: Pulmonary aspergillosis in two COVID-19 patients from Kuwait. publication-title: Access. Microbiol. doi: 10.1099/acmi.0.000201 – volume: 7 year: 2021 ident: B40 article-title: A fatal case of Rhizopus azygosporus pneumonia following COVID-19. publication-title: J. Fungi doi: 10.3390/jof7030174 – volume: 7 start-page: 39 year: 2021 ident: B43 article-title: Proven pulmonary aspergillosis in a COVID-19 patient: a case report. publication-title: Curr. Med. Mycol. doi: 10.18502/cmm.7.2.7031 – volume: 395 start-page: 507 year: 2020 ident: B17 article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. publication-title: Lancet doi: 10.1016/S0140-6736(20)30211-7 – volume: 48 start-page: 647 year: 2020 ident: B82 article-title: Successful management of the first reported case in Austria of COVID-19 with ARDS. publication-title: Infection doi: 10.1007/s15010-020-01458-9 – volume: 5 year: 2021 ident: B4 article-title: COVID-19-associated pulmonary aspergillosis: a case report from the COVID-19 surveillance program. publication-title: Univ. Louisville J. Respir. Infect. doi: 10.18297/jri/vol5/iss1/31 – volume: 97 start-page: 326 year: 2020 ident: B22 article-title: Oral mucosal lesions in a COVID-19 patient: new signs or secondary manifestations? publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2020.06.012 – volume: 22 year: 2020 ident: B1 article-title: Fatal coronavirus disease 2019-associated pulmonary aspergillosis; a report of two cases and review of the literature. publication-title: IDCases doi: 10.1016/j.idcr.2020.e00935 – volume: 8 start-page: 336 year: 2010 ident: B57 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. publication-title: Int. J. Surg. doi: 10.1016/j.ijsu.2010.02.007 – volume: 30 year: 2020 ident: B81 article-title: Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. publication-title: J. Mycol. Med. doi: 10.1016/j.mycmed.2020.101039 – volume: 53 start-page: 382 year: 2021 ident: B97 article-title: Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19. publication-title: Infect. Dis. doi: 10.1080/23744235.2021.1890331 – volume: 119 year: 2022 ident: B75 article-title: COVID-19 therapeutics: challenges and directions for the future. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.2119893119 – volume: 31 start-page: 19 year: 2021 ident: B25 article-title: Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.07.001 – volume: 7 year: 2021 ident: B18 article-title: Mixed etiology COVID-19 associated pulmonary aspergillosis (CAPA)—a case report and brief review of the literature. publication-title: J. Fungi doi: 10.3390/jof7100877 – volume: 8 year: 2020 ident: B84 article-title: The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: a case report. publication-title: J. Investig. Med. High Impact Case Rep. doi: 10.1177/2324709620930540 – volume: 38 year: 2020 ident: B9 article-title: Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: a diagnostic challenge. publication-title: Travel. Med. Infect. Dis. doi: 10.1016/j.tmaid.2020.101752 – volume: 12 year: 2020 ident: B49 article-title: Rhino-orbital mucormycosis associated with COVID-19. publication-title: Cureus doi: 10.7759/cureus.10726 – volume: 6 year: 2020 ident: B50 article-title: Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report. publication-title: J. Fungi doi: 10.3390/jof6020079 – volume: 23 year: 2021 ident: B102 article-title: Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. publication-title: Microbes Infect. doi: 10.1016/j.micinf.2021.104806 – volume: 57 year: 2021 ident: B76 article-title: A case series of post COVID-19 mucormycosis—a neurological prospective. publication-title: Egypt. J. Neurol. Psychiatry Neurosurg. doi: 10.1186/s41983-021-00355-8 – volume: 32 start-page: 64 year: 2021 ident: B37 article-title: Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2021.03.006 – volume: 25 start-page: 85 year: 2021 ident: B53 article-title: COVID-19 among people living with HIV: a systematic review. publication-title: AIDS Behav. doi: 10.1007/s10461-020-02983- – volume: 8 start-page: 475 year: 2020 ident: B103 article-title: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30079-5 – volume: 14 year: 2021 ident: B74 article-title: COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? publication-title: BMJ Case Rep. doi: 10.1136/bcr-2021-241663 – volume: 6 year: 2020 ident: B96 article-title: Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. publication-title: J. Fungi doi: 10.3390/jof6030098 – volume: 8 start-page: 249 year: 2021 ident: B14 article-title: Fungal sinusitis post COVID 19 – a case series from a diagnostic microbiology laboratory. publication-title: Indian J. Med. Microbiol. doi: 10.18231/j.ijmr.2021.051 – volume: 20 year: 2020 ident: B3 article-title: The potential impacts of obesity on COVID-19. publication-title: Clin. Med. doi: 10.7861/clinmed.2020-0239 – volume: 105 start-page: 540 year: 2021 ident: B24 article-title: SARS-CoV-2 and immune-microbiome interactions: lessons from respiratory viral infections. publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2021.02.071 – volume: 31 start-page: 24 year: 2021 ident: B13 article-title: COVID-19 associated pulmonary aspergillosis in ICU patients: report of five cases from Argentina. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.11.003 – volume: 13 year: 2021 ident: B98 article-title: A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. publication-title: Cureus doi: 10.7759/cureus.13163 – volume: 23 year: 2021 ident: B10 article-title: Mucormycosis associated with covid19 in two kidney transplant patients. publication-title: Transpl. Infect. Dis. doi: 10.1111/tid.13652 – volume: 34 year: 2021 ident: B93 article-title: Photobiomodulation therapy and antimicrobial photodynamic therapy for orofacial lesions in patients with COVID-19: a case series. publication-title: Photodiagnosis. Photodyn. Ther. doi: 10.1016/j.pdpdt.2021.102281 – volume: 31 start-page: 29 year: 2021 ident: B31 article-title: Invasive pulmonary aspergillosis and hyperthermia in an immunocompetent patient with COVID-19. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.11.004 – volume: 11 start-page: 448 year: 2019 ident: B35 article-title: Unraveling the importance of molecules of natural origin in antifungal drug development through targeting ergosterol biosynthesis pathway. publication-title: Iran. J. Microbiol. doi: 10.18502/ijm.v11i6.2216 – volume: 27 start-page: 911 year: 2021 ident: B34 article-title: COVID-19-associated pulmonary aspergillosis in a Japanese man: a case report. publication-title: J. Infect. Chemother. doi: 10.1016/j.jiac.2021.02.026 – volume: 100 year: 2021 ident: B80 article-title: Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: case report. publication-title: Medicine doi: 10.1097/MD.0000000000025173 – volume: 25 year: 2021 ident: B6 article-title: Trichosporon asahii fungemia and COVID-19 co-infection: an emerging fungal pathogen; case report and review of the literature. publication-title: IDCases doi: 10.1016/j.idcr.2021.e01244 – volume: 49 start-page: 1055 year: 2021 ident: B64 article-title: A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. publication-title: Infection doi: 10.1007/s15010-020-01561-x – volume: 31 start-page: 11 year: 2021 ident: B56 article-title: Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: a lethal combination. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.06.005 – volume: 31 year: 2021 ident: B42 article-title: Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient–case report and review of literature. publication-title: J. Mycol. Med. doi: 10.1016/j.mycmed.2021.101125 – volume: 37 start-page: 266 year: 2021 ident: B66 article-title: Human immunodeficiency virus and severe acute respiratory syndrome coronavirus 2 coinfection: a systematic review of the literature and challenges. publication-title: AIDS Res. Hum. Retrovir. doi: 10.1089/aid.2020.0284 – volume: 2 start-page: 2414 year: 2020 ident: B65 article-title: Detected SARS-CoV-2 in ascitic fluid followed by cryptococcemia: a case report. publication-title: SN Compr. Clin. Med. doi: 10.1007/s42399-020-00574-9 – volume: 13 start-page: 7745 year: 2021 ident: B68 article-title: Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis. publication-title: Aging doi: 10.18632/aging.202742 – volume: 73 start-page: e1645 year: 2020 ident: B32 article-title: Invasive fungal disease complicating Coronavirus Disease 2019: when it rains, it spores. publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa1342 – volume: 31 start-page: 6 year: 2021 ident: B85 article-title: COVID-19 associated pulmonary aspergillosis (CAPA): an Australian case report. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.06.002 – volume: 39 start-page: 380 year: 2021 ident: B61 article-title: Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. publication-title: Indian J. Med. Microbiol. doi: 10.1016/j.ijmmb.2021.05.009 – volume: 20 start-page: 1951 year: 2020 ident: B86 article-title: Fungal infections in COVID-19-positive patients: a lack of optimal treatment options. publication-title: Curr. Top. Med. Chem. doi: 10.2174/156802662022200917110102 – volume: 15 start-page: 2378 year: 2020 ident: B69 article-title: Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. publication-title: Radiol. Case Rep. doi: 10.1016/j.radcr.2020.09.026 – volume: 24 year: 2020 ident: B99 article-title: Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. publication-title: Crit. Care doi: 10.1186/s13054-020-03046-7 – volume: 186 start-page: 109 year: 2021 ident: B12 article-title: COVID-19-associated histoplasmosis in an AIDS patient. publication-title: Mycopathologia doi: 10.1007/s11046-020-00505-1 – volume: 7 start-page: 46 year: 2020 ident: B41 article-title: A case report of COVID-19 associated pulmonary mucormycosis. publication-title: Arch. Clin. Cases doi: 10.22551/2020.28.0703.10172 – volume: 51 start-page: 632 year: 2021 ident: B44 article-title: Novel pathogens, same old habits. A call for evidence-based research in the fight against COVID-19. publication-title: Infect. Dis. Now doi: 10.1016/j.idnow.2021.01.004 – volume: 63 start-page: 766 year: 2020 ident: B59 article-title: COVID−19−associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID−19 pneumonia: an observational study from Pakistan. publication-title: Mycoses doi: 10.1111/myc.13135 – volume: 63 start-page: 1144 year: 2020 ident: B23 article-title: Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital. publication-title: Mycoses doi: 10.1111/myc.13155 – volume: 8 year: 2020 ident: B36 article-title: Gender differences in patients with COVID-19: focus on severity and mortality. publication-title: Front. Public Health doi: 10.3389/fpubh.2020.00152 – volume: 2 start-page: 93 year: 2021 ident: B2 article-title: Coronavirus disease (COVID-19) associated rhinocerebral mucormycosis and complications: a case report. publication-title: Int. J. Clin. Res. doi: 10.38179/ijcr.v2i1.102 – volume: 26 start-page: 1395 year: 2020 ident: B33 article-title: Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2020.06.025 – volume: 37 start-page: e40 year: 2021 ident: B51 article-title: Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. publication-title: Ophthalmic Plast. Reconstr. Surg. doi: 10.1097/IOP.0000000000001889 – volume: 48 start-page: 319 year: 2021 ident: B11 article-title: Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. publication-title: J. Neuroradiol. doi: 10.1016/j.neurad.2021.05.007 – volume: 9 year: 2021 ident: B62 article-title: Oral candidiasis caused by ciclesonide in a patient with COVID-19 pneumonia: a case report and literature review. publication-title: SAGE Open Med. Case Rep. doi: 10.1177/2050313X211048279 – volume: 37 start-page: 41 year: 2020 ident: B67 article-title: Fungal co-infection in COVID-19 patients: should we be concerned? publication-title: Rev. Iberoam. Micol. doi: 10.1016/j.riam.2020.07.001 – year: 2020 ident: B30 article-title: Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the Coronavirus Study Group. publication-title: bioRxiv Preprint doi: 10.1101/2020.02.07.937862 – volume: 6 year: 2020 ident: B91 article-title: Fungal infections complicating COVID-19: with the rain comes the spores. publication-title: J. Fungi doi: 10.3390/jof6040279 – volume: 185 start-page: 1077 year: 2020 ident: B60 article-title: Fatal invasive pulmonary Aspergillosis in COVID-19 patient with acute myeloid leukemia in Iran. publication-title: Mycoses doi: 10.1007/s11046-020-00493-2 – volume: 71 start-page: 2459 year: 2020 ident: B73 article-title: Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa530 – year: 2021 ident: B79 article-title: Title of the article: paranasal mucormycosis in COVID-19 patient. publication-title: Indian J. Otolaryngol. Head Neck Surg. doi: 10.1007/s12070-021-02574-0 – volume: 82 year: 2021 ident: B46 article-title: Sino-orbital mucormycosis in a COVID-19 patient: a case report. publication-title: Int. J. Surg. Case Rep. doi: 10.1016/j.ijscr.2021.105957 – volume: 31 start-page: 2 year: 2021 ident: B71 article-title: Invasive pulmonary aspergillosis complicating COVID-19 in the ICU-A case report. publication-title: Med. Mycol. Case Rep. doi: 10.1016/j.mmcr.2020.05.001 – volume: 183 start-page: 71 year: 2020 ident: B27 article-title: Classification of the cutaneous manifestations of COVID−19: a rapid prospective nationwide consensus study in Spain with 375 cases. publication-title: Br. J. Dermatol. doi: 10.1111/bjd.19163 – volume: 8 year: 2021 ident: B63 article-title: COVID-19 and cardiomyopathy: a systematic review. publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2021.695206 – volume: 27 year: 2020 ident: B72 article-title: COVID-19 evaluation by low-dose high resolution CT scans protocol. publication-title: Acad. Radiol. doi: 10.1016/j.acra.2020.04.016 – volume: 21 year: 2020 ident: B38 article-title: Determination of COVID-19 prevalence with regards to age range of patients referring to the hospitals located in western Tehran, Iran. publication-title: Gene Rep. doi: 10.1016/j.genrep.2020.100910 – volume: 42 start-page: 1503 year: 2021 ident: B39 article-title: A case series on post-COVID deadly fungal infection: mucormycosis. publication-title: Int. J. Otorhinolaryngol. Head Neck Surg. doi: 10.18203/issn.2454-5929.ijohns20213287 – volume: 20 start-page: 697 year: 2020 ident: B45 article-title: Clinical and virological data of the first cases of COVID-19 in Europe: a case series. publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30200-0 – volume: 32 year: 2021 ident: B94 article-title: Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. publication-title: Respir. Med. Case Rep. doi: 10.1016/j.rmcr.2021.101367 – volume: 12 start-page: 85 year: 2021 ident: B5 article-title: Rhinocerebral mucormycosis and COVID-19 pneumonia. publication-title: J. Med. Case Rep. doi: 10.14740/jmc3637 – year: 2021 ident: B19 article-title: Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. publication-title: Orbit doi: 10.1080/01676830.2021.1903044 – volume: 8 year: 2020 ident: B15 article-title: An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19. publication-title: J. Investig. Med. High Impact Case Rep. doi: 10.1177/2324709620972244 – volume: 13 year: 2021 ident: B88 article-title: Coronavirus disease-associated mucormycosis from a tertiary care hospital in India: a case series. publication-title: Cureus doi: 10.7759/cureus.16152 – volume: 2 start-page: 270 year: 2003 ident: B104 article-title: The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome. publication-title: Chin. J. Respir. Crit. Care Med. |
| SSID | ssj0000402000 |
| Score | 2.491252 |
| SecondaryResourceType | review_article |
| Snippet | Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts.... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 888452 |
| SubjectTerms | Aspergillus co-infection COVID-19 fungal infection Microbiology systematic review |
| Title | Fungal Infection in Co-infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review |
| URI | https://www.proquest.com/docview/2694417163 https://pubmed.ncbi.nlm.nih.gov/PMC9298665 https://doaj.org/article/9bee12fed649463d8555600ef0d13c87 |
| Volume | 13 |
| WOSCitedRecordID | wos000829411900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1664-302X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402000 issn: 1664-302X databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-302X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402000 issn: 1664-302X databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96KPgifuL6cUTwSSi326RN4tu53uKB3h2o576FNJlyhSMr190TX_zbnUl6y_ZFX4QSaJPSNDPp_KYz-YWxNwEhQ4NmrwiovYV0uioa49BV0WWrhNOyTSn_55_UyYleLs3ZzlZflBOW6YHzwB2YBmBWthBqaWQtgq4qMtLQTsNMeJ3WkSPq2XGm0jeY3KLpEMZEL8ygmDrfoD9YlqgbWlblyBAlvv4RyBynSO7YnMUDdn8Ai_wwd_IhuwXxEbubt4_89ZhtFjhTsf54SKiKvIt8vipyghUEfpZJU3v-vVtf8Pnp-fGHYmbe8cPIT6_pIwE_-arlc7RkPCPx_iCd0D8z6LmLgX_ZUj3zHEd4wr4tjr7OPxbDNgqFl7JcU2mcpoGvlNEVyKZqpQ9QAk4-rxR4itUJYWYOD9GG2jkBIJxrg3a-FE_ZXlxFeMa4rgPixcZ5oTx6VtrpgIAOauXAgXRhwqY3Y2r9wDFOW11cWvQ1SAw2icGSGGwWw4S93d7yIxNs_K3xexLUtiFxY6cLqDF20Bj7L42ZsNc3YrY4lyhA4iKsNr2lVb2S-IPEhKmR_EdPHNfE7iKxciPOJO7A5_-jiy_YPXrrlBZcv2R766sNvGJ3_PW666_22W211PtJ4bH8_PvoD7yaBr8 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fungal+Infection+in+Co-infected+Patients+With+COVID-19%3A+An+Overview+of+Case+Reports%2FCase+Series+and+Systematic+Review&rft.jtitle=Frontiers+in+microbiology&rft.au=Seyedjavadi%2C+Sima+Sadat&rft.au=Bagheri%2C+Parmida&rft.au=Nasiri%2C+Mohammad+Javad&rft.au=Razzaghi-Abyaneh%2C+Mehdi&rft.date=2022-07-06&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-302X&rft.volume=13&rft_id=info:doi/10.3389%2Ffmicb.2022.888452&rft_id=info%3Apmid%2F35875562&rft.externalDocID=PMC9298665 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon |